PURPOSE:Patients with stage II/III human epidermal growth factor receptor 2 (HER2)-positive or triple-negative breast cancer (TNBC) frequently receive neoadjuvant therapy (NAT). Although pathologic complete response (pCR) correlates with improved outcomes, many non-pCR patients have long-term survival. Circulating tumor-DNA (ctDNA) minimal residual disease (MRD) assessment may provide additional or superior risk stratification. METHODS:Pathologic Response Evaluation and Detection in Circulating Tumor-DNA is a prospective, multicenter study evaluating ctDNA as a biomarker of treatment response using a tumor-informed, ultrasensitive (<100 parts per million) assay. The primary objective was to determine whether the negative predictive value (NPV) of post-NAT ctDNA for pCR was ≥90%. A prespecified secondary objective for the TNBC cohort was to assess associations between ctDNA and 5-year invasive disease-free survival (IDFS). ctDNA was evaluated at baseline, after NAT before surgery, and after surgery. RESULTS:Of 227 enrolled patients, 220 were evaluable for pCR (48% HER2-positive; 52% TNBC) and 91 patients (41%) had pCR. The primary objective was not met. Although all patients with pCR were ctDNA-negative after NAT, 40% of non-pCR patients were also ctDNA-negative (NPV, 60% [95% CI, 0.50 to 0.69]). However, the prespecified secondary objective was met. Detectable ctDNA after NAT was prognostic for recurrence (hazard ratio [HR], 8.9 [95% CI, 2.4 to 33]; P = .001), independent of pCR. Additionally, detectable ctDNA after surgery identified patients at extremely high recurrence risk (HR, 128 [95% CI, 15 to 1,083]; P < .001), while ctDNA-negative patients after surgery had 94% 5-year IDFS. CONCLUSION:In HER2-positive breast cancer and TNBC, ctDNA after NAT does not discriminate pCR from non-pCR. However, ctDNA provides markedly superior prognostic stratification, identifying patients with exceptional outcomes and those at extreme risk. These findings support ctDNA-guided therapeutic de-escalation and escalation strategies.
INTRODUCTION:Endoscopic retrograde cholangiopancreatography (ERCP) is essential for pancreaticobiliary disease management; however, there are risks associated with the procedure, particularly post-ERCP pancreatitis (PEP). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), widely used in metabolic disease, possess anti-inflammatory and cytoprotective properties that may influence periprocedural outcomes. Their impact on ERCP adverse events remains unclear; therefore, we aimed to investigate whether GLP-1 influences short-term postprocedural outcomes using a large real-world database. METHODS:We conducted a retrospective cohort study using the TriNetX US Collaborative Network, identifying adults (18 y or older) who underwent ERCP between January 2015 and December 2024. Patients were categorized based on documented preprocedure GLP-1 receptor agonist exposure. Propensity score matching (1:1) was performed using demographic, clinical, procedural, and pharmacologic covariates to minimize confounding, yielding 2 well-balanced cohorts. Thirty-day post-ERCP outcomes-including acute pancreatitis, cholangitis, sepsis, gastrointestinal bleeding, biliary stricture, choledocholithiasis, and repeat ERCP-were assessed using ICD-10 and CPT codes. Risk ratios (RRs) and hazard ratios (HRs) with 95% CIs were calculated. RESULTS:Of 250,502 patients with ERCP screened, 21,818 propensity-matched individuals were included in the final analysis. Compared with matched nonusers, patients receiving GLP-1 receptor agonists had significantly lower 30-day rates of all major ERCP-related adverse events. GLP-1 RA exposure was associated with reduced risks of acute pancreatitis (RR: 0.47, 95% CI: 0.43-0.51), cholangitis (RR: 0.56, 95% CI: 0.50-0.62), sepsis (RR: 0.51, 95% CI: 0.46-0.57), gastrointestinal bleeding (RR: 0.49, 95% CI: 0.40-0.61), biliary stricture (RR: 0.52, 95% CI: 0.48-0.55), repeat ERCP (RR: 0.53, 95% CI: 0.48-0.58), and choledocholithiasis (RR: 0.66, 95% CI: 0.62-0.71). Results were consistent across time-to-event analyses over the 30-day follow-up period. CONCLUSIONS:In this large real-world analysis, preprocedure GLP-1 RA therapy was associated with markedly reduced 30-day ERCP-related adverse events, most notably PEP. These findings highlight a potential protective role of GLP-1 signaling in the periprocedural inflammatory response and support prospective studies evaluating GLP-1 RAs as adjunctive prophylactic agents in ERCP. Further prospective studies are needed.
Background Periprosthetic fractures (PPFs) are a significant complication following total hip arthroplasty (THA) and knee arthroplasty (TKA), resulting in substantial patient morbidity. This study aims to quantify the burden of PPF, describe surgical management trends, and identify key patient risk factors in the United States population. Methods A retrospective review of patients undergoing primary unilateral THA or TKA from 2016 to 2022 was performed using the PearlDiver national database. The primary outcome was the burden of PPF in both THA and TKA. Multivariate analyses were performed to identify risk factors for PPF, and univariate analyses were performed to compare outcomes across surgical treatments: open reduction and internal fixation (ORIF), revision, and revision + ORIF combined. Results From 2016 to 2022, the burden of THA PPFs increased from 884 (1.35%) to 1,622 (1.50%), an 11.1% relative increase. The burden of TKA PPFs increased from 669 (0.55%) to 1,147 (0.61%), a 10.9% relative increase. In both populations, increased age, female sex, and higher comorbidity burden were associated with increased risk of PPF. The most common fixation method of PPF after THA was revision, with 2,712 (77.6%) cases, followed by revision + ORIF with 489 (14.0%) cases and ORIF with 295 (8.4%) cases. The most common fixation method of PPF after TKA was revision, with 856 (51.5%) cases, followed by ORIF with 767 (46.2%) cases and revision + ORIF with 38 (2.3%) cases. High 90-day complication rates were observed across treatments. Conclusion The burden of PPFs after THA and TKA increased by approximately 11% from 2016 to 2022, although this did not achieve statistical significance. Targeted strategies for preventing PPFs in high-risk patients and further investigation into optimal treatment methods are warranted, given the high morbidity associated with these injuries.
Background: Acute myeloid leukemia (AML) is the most prevalent type of leukemia, which primarily affects older patients. Because the definition of ‘elderly’ AML varies across the literature, from ≥60 years in some cooperative-group studies to a strict ≥ 75-year threshold in the pivotal VIALE-A trial, we adopt ≥ 60 years as our working definition. Despite recent advancements, the 5-year overall survival (OS) of AML patients is just 30% and declines to 5–10% in patients older than 65 years at diagnosis. The main objective of treatment in older individuals is to achieve complete remission (CR) and maintain a good quality of life. Discussion: Traditionally, intensive chemotherapy (IC) has been used for management of AML since the 1970s. Patients older in age are often not eligible for IC due to factors such as advanced age, comorbidities, and disease characteristics such as high-risk cytogenetics and adverse risk mutations. When considering patients for intensive (and alternative) chemotherapy and allogeneic hematopoietic stem cell transplantation (alloHSCT), we need to consider a standardized fitness assessment tool, which would significantly improve our capacity to individualize treatment strategies and design patient-specific clinical trials. Tools such as performance status, the Ferrara criteria, and comprehensive geriatric assessment (CGA) can help evaluate the baseline comorbidity burden in elderly patients. The discovery of hypomethylating agents (HMAs) like azacitidine and decitabine and BCL-2 inhibitors such as venetoclax has been pivotal in the treatment of elderly AML patients unfit for IC. As our knowledge advances in understanding the pathogenesis of AML, we are learning about new genetic mutations and molecular targets that play an important role in the development of AML. In this revised review, we explicitly separate drugs that are FDA-approved and have been studied specifically in older or unfit AML patients from drugs that are approved but lack dedicated efficacy data in this population and from agents that remain investigational; each tier is summarized in a comparative table of results in all-comers versus results in older/unfit patients and limitations. Advances in reduced-intensity conditioning and GVHD prophylaxis have extended allogeneic transplantation to select fit older patients, while low-dose chemotherapy to manage cell count and supportive care remain vital for non-aggressive pathways. Conclusions: In our review, we have outlined current treatment options for older AML patients, with an emphasis on distinguishing which regimens are supported by dedicated evidence in this population, particularly those unfit for IC.
DHP107 is an oral paclitaxel enabling administration of paclitaxel without Cremophor EL, a vehicle used to improve the solubility of intravenous (IV) paclitaxel. The randomized phase II OPERA study investigated the efficacy and safety of DHP107 versus IV paclitaxel in patients with HER2-negative breast cancer. OPERA was conducted in the USA and Czech Republic. Patients were ≥ 18 years, with measurable disease, and histologically or cytologically confirmed recurrent or metastatic breast cancer with any tumor hormone receptor status. Patients were randomized 2:1 to DHP107 (200 mg/m2 po bid with premedication if needed on days 1, 8, and 15, every 28 days) or IV paclitaxel (80 mg/m2 with standard premedication on days 1, 8, and 15 every 28 days). The primary objective was DHP107 efficacy; secondary objectives included DHP107 safety and tolerability. 72 patients were randomized, 48 to DHP107 and 24 to IV paclitaxel. There was one complete response and 11 partial responses with DHP107 (objective response rate [ORR 25.0